E. Ohman J:Or Asset Management Ab Gilead Sciences, Inc. Transaction History

E. Ohman J:Or Asset Management Ab

$4.03 Trillion
Q2 2024

A detailed history of E. Ohman J:Or Asset Management Ab transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, E. Ohman J:Or Asset Management Ab holds 53,000 shares of GILD stock, worth $4.46 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

53,000

Previous 50,900 4.13%

Holding current value

$4.46 Million

Previous $3.73 Billion 2.47%

% of portfolio

0.09%

Previous 0.1%

55 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$63.15 - $72.88 $132,615 - $153,048	2,100 Added 4.13%	53,000 $3.64 Billion
Q1 2024 May 14, 2024	BUY	$71.58 - $87.29 $121,686 - $148,393	1,700 Added 3.46%	50,900 $3.73 Billion
Q4 2023 Feb 15, 2024	SELL	$73.27 - $83.09 $622,795 - $706,265	-8,500 Reduced 14.73%	49,200 $3.99 Billion
Q3 2023 Feb 06, 2024	BUY	$73.94 - $80.67 $4.27 Million - $4.65 Million	57,700 New	57,700 $4.32 Billion
Q2 2023 Apr 05, 2024	BUY	$76.01 - $86.7 $98,813 - $112,710	1,300 Added 2.3%	57,700 $4.45 Billion
Q1 2023 Apr 05, 2024	BUY	$77.31 - $88.08 $239,661 - $273,048	3,100 Added 5.82%	56,400 $4.68 Billion
Q4 2022 Apr 05, 2024	SELL	$62.32 - $89.47 $87,248 - $125,258	-1,400 Reduced 2.56%	53,300 $4.58 Billion
Q3 2022 Apr 05, 2024	SELL	$59.54 - $68.01 $95,264 - $108,816	-1,600 Reduced 2.84%	54,700 $3.37 Billion
Q1 2022 Apr 05, 2024	SELL	$57.92 - $72.58 $214,304 - $268,546	-3,700 Reduced 6.17%	56,300 $3.35 Billion
Q4 2021 Apr 05, 2024	BUY	$64.88 - $73.64 $162,200 - $184,100	2,500 Added 4.35%	60,000 $4.36 Billion
Q3 2021 Apr 05, 2024	BUY	$67.69 - $73.03 $270,760 - $292,120	4,000 Added 7.48%	57,500 $4.02 Billion
Q2 2021 Apr 05, 2024	BUY	$63.47 - $69.35 $171,369 - $187,244	2,700 Added 5.31%	53,500 $3.68 Billion
Q1 2021 Apr 05, 2024	SELL	$60.0 - $68.46 $240,000 - $273,840	-4,000 Reduced 7.3%	50,800 $3.28 Billion
Q4 2020 Apr 05, 2024	BUY	$56.65 - $64.55 $232,265 - $264,655	4,100 Added 8.09%	54,800 $3.19 Billion
Q3 2020 Apr 05, 2024	BUY	$62.1 - $78.08 $117,990 - $148,352	1,900 Added 3.89%	50,700 $3.2 Billion
Q2 2020 Apr 05, 2024	BUY	$72.34 - $84.0 $267,658 - $310,800	3,700 Added 8.2%	48,800 $3.75 Billion
Q1 2020 Apr 05, 2024	SELL	$62.63 - $80.22 $1.06 Million - $1.36 Million	-16,900 Reduced 27.26%	45,100 $3.37 Billion
Q4 2019 Apr 05, 2024	BUY	$61.62 - $67.78 $258,804 - $284,676	4,200 Added 7.27%	62,000 $4.03 Billion
Q3 2019 Apr 05, 2024	BUY	$62.51 - $69.0 $243,789 - $269,100	3,900 Added 7.24%	57,800 $3.66 Billion
Q2 2019 Apr 05, 2024	BUY	$61.87 - $69.38 $86,618 - $97,132	1,400 Added 2.67%	53,900 $3.64 Billion
Q1 2019 Apr 05, 2024	SELL	$62.53 - $70.05 $43,771 - $49,035	-700 Reduced 1.32%	52,500 $3.41 Billion
Q4 2018 Apr 05, 2024	SELL	$60.54 - $79.0 $587,238 - $766,300	-9,700 Reduced 15.42%	53,200 $3.33 Billion
Q3 2018 Apr 05, 2024	BUY	$71.28 - $78.92 $1.49 Million - $1.65 Million	20,900 Added 49.76%	62,900 $4.86 Billion
Q2 2018 Apr 05, 2024	BUY	$64.88 - $75.68 $798,024 - $930,864	12,300 Added 41.41%	42,000 $2.98 Billion
Q1 2018 Apr 05, 2024	SELL	$72.84 - $88.8 $109,260 - $133,200	-1,500 Reduced 4.81%	29,700 $2.24 Billion
Q4 2017 Apr 05, 2024	SELL	$71.15 - $83.52 $305,945 - $359,136	-4,300 Reduced 12.11%	31,200 $2.24 Billion
Q3 2017 Apr 05, 2024	BUY	$72.11 - $85.47 $50,477 - $59,829	700 Added 2.01%	35,500 $2.88 Billion
Q1 2017 Apr 05, 2024	BUY	N/A	5,000 Added 16.78%	34,800 $2.36 Billion
Q4 2016 Apr 05, 2024	BUY	N/A	1,900 Added 6.81%	29,800 $2.13 Billion
Q2 2016 Apr 05, 2024	BUY	N/A	1,700 Added 6.49%	27,900 $2.33 Billion
Q1 2016 Apr 05, 2024	SELL	N/A	-1,600 Reduced 5.76%	26,200 $2.41 Billion
Q3 2015 Apr 05, 2024	SELL	N/A	-2,200 Reduced 7.33%	27,800 $2.73 Billion
Q2 2015 Apr 05, 2024	SELL	N/A	-2,400 Reduced 7.41%	30,000 $3.51 Billion
Q4 2014 Apr 05, 2024	SELL	N/A	-2,200 Reduced 6.36%	32,400 $3.09 Billion
Q2 2014 Apr 05, 2024	SELL	N/A	-1,700 Reduced 4.68%	34,600 $2.87 Billion
Q1 2014 Apr 05, 2024	SELL	N/A	-1,900 Reduced 4.97%	36,300 $2.57 Billion
Q4 2013 Apr 05, 2024	SELL	N/A	-200 Reduced 0.52%	38,200 $2.87 Billion
Q3 2013 Apr 05, 2024	BUY	N/A	1,600 Added 4.35%	38,400 $2.41 Billion
Q2 2013 Apr 05, 2024	SELL	N/A	-4,400 Reduced 10.68%	36,800 $1.89 Billion
Q1 2013 Apr 05, 2024	BUY	N/A	21,600 Added 110.2%	41,200 $2.02 Billion
Q3 2012 Apr 05, 2024	BUY	N/A	1,900 Added 10.73%	19,600 $1.3 Billion
Q2 2012 Apr 05, 2024	SELL	N/A	-2,700 Reduced 13.24%	17,700 $908 Million
Q1 2012 Apr 05, 2024	BUY	N/A	6,400 Added 45.71%	20,400 $997 Million
Q3 2011 Apr 05, 2024	SELL	N/A	-2,700 Reduced 16.17%	14,000 $543 Million
Q1 2011 Apr 05, 2024	BUY	N/A	2,800 Added 20.14%	16,700 $711 Million
Q4 2010 Apr 05, 2024	SELL	N/A	-2,400 Reduced 14.72%	13,900 $504 Million
Q2 2010 Apr 05, 2024	BUY	N/A	3,500 Added 27.34%	16,300 $559 Million
Q4 2009 Apr 05, 2024	SELL	N/A	-2,300 Reduced 15.23%	12,800 $554 Million
Q2 2009 Apr 05, 2024	BUY	N/A	2,500 Added 19.84%	15,100 $707 Million
Q4 2008 Apr 05, 2024	BUY	N/A	1,600 Added 14.55%	12,600 $644 Million
Q3 2008 Apr 05, 2024	SELL	N/A	-1,800 Reduced 14.06%	11,000 $501 Million
Q2 2008 Apr 05, 2024	BUY	N/A	3,000 Added 30.61%	12,800 $678 Million
Q4 2007 Apr 05, 2024	BUY	N/A	1,800 Added 22.5%	9,800 $451 Million
Q2 2007 Apr 05, 2024	BUY	N/A	4,000 Added 100.0%	8,000 $310 Million
Q4 2006 Apr 05, 2024	SELL	N/A	-45,200	4,000 $260 Million

Others Institutions Holding GILD

# of Institutions

1,880

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $105B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of E. Ohman J:Or Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on E. Ohman J:Or Asset Management Ab with notifications on news.

Account

E. Ohman J:Or Asset Management Ab Gilead Sciences, Inc. Transaction History